author-photo

Ya-Chi Chen

Hoffmann-La Roche

11

Papers

166

Citations

Citation Trend

Filter By

Papers (9) Sort By

Journal Conference Others

Time‐to‐event modelling of effect of codrituzumab on overall survival in patients with hepatocellular carcinoma

2018 British Journal of Clinical Pharmacology
Show All
- Source
- Cite
- Save
Citations (2)
Combining expression of GPC3 in tumors and CD16 on NK cells from peripheral blood to identify patients responding to codrituzumab

2018 Oncotarget
Show All
- Source
- Cite
- Save
Citations (11)
Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC)

2017 Cancer Chemotherapy and Pharmacology
Show All
- Source
- Cite
- Save
Citations (15)
Abstract 3944: Combining tumor glypican-3 expression and CD16 Expression on NK cells from peripheral blood to identify patients responding to codrituzumab/GC33/RO5137382

2016 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma

2016 Journal of Hepatology
Show All
- Source
- Cite
- Save
Citations (66)
The effect of mild to moderate renal impairment on the pharmacokinetics of the nucleoside analog hepatitis C virus polymerase inhibitor mericitabine.

2014 Drug Development Research
Show All
- Source
- Cite
- Save
Citations (0)
Biomarker analysis of a randomized, placebo-controlled, double-blind, multicenter phase II trial of intravenous RO5137382/GC33 at 1600 mg Q2W in previously treated patients with unresectable advanced or metastatic hepatocellular carcinoma (HCC) (NCT01507168).

2014 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Phase Ib study of RO5137382/GC33 in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC) (NCT00976170).

2014 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (2)
Randomized phase II trial of intravenous RO5137382/GC33 at 1600 mg every other week and placebo in previously treated patients with unresectable advanced hepatocellular carcinoma (HCC; NCT01507168).

2014 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (15)